KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Gross Margin (2020 - 2025)

Moderna (MRNA) has disclosed Gross Margin for 6 consecutive years, with 33.33% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin fell 340.0% to 33.33% in Q4 2025 year-over-year; TTM through Dec 2025 was 55.35%, a 125.0% decrease, with the full-year FY2025 number at 55.35%, up 59.0% from a year prior.
  • Gross Margin was 33.33% for Q4 2025 at Moderna, down from 79.63% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 90.04% in Q1 2021 to a low of 112.5% in Q2 2023.
  • A 5-year average of 47.52% and a median of 64.61% in 2023 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: plummeted -18342bps in 2023, then surged 14716bps in 2024.
  • Moderna's Gross Margin stood at 86.8% in 2021, then fell by -28bps to 62.27% in 2022, then grew by 8bps to 66.95% in 2023, then crashed by -45bps to 36.73% in 2024, then fell by -9bps to 33.33% in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Gross Margin are 33.33% (Q4 2025), 79.63% (Q3 2025), and 16.2% (Q2 2025).